Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma

Launched by ASSIUT UNIVERSITY · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a specific protein called CD44 and its role in renal cell carcinoma (RCC), a type of kidney cancer. Researchers want to understand how CD44 is expressed in different types of RCC and how it relates to other factors that might affect a patient’s condition and survival. By studying the levels of CD44 in tumors, the team hopes to learn more about how it could help predict patient outcomes.

To participate in this trial, you must be at least 18 years old and have complete medical information about your condition. However, if you have other types of cancer or if you haven't been followed closely after kidney surgery for at least three years, you won't be eligible to join. While the trial is not yet recruiting participants, those who do take part will help contribute to important research that could improve understanding and treatment of kidney cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient must be more than 18 years
• • Patients with complete pathological data
• Exclusion Criteria:
• • The presence of any other organ malignancies
• • Patients who lost follow-up after nephrectomy less than 3-year,
• • Patients with incomplete pathological data